Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
Home
Business Strategy
Business Strategy
Business Strategy
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
pharmaquotient.com
-
17 September 2024
Business Strategy
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
Business Strategy
AbbVie Invested €150 M to Develop R&D Facility in Germany.
Business Strategy
Daiichi Sankyo Decided for RD Novare Closure
No posts to display
Most Read
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024